all

Novartis received FDA approval for a label update that will allow for use of Leqvio ^® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.

Call for Nominations is open for the National Lipid Association Board of Directors and Chapter officers and will be extended until 5 pm ET on February 15, 2025.

To submit a nomination and for more information on the process, visit lipid.org/nominate.

The following is a National Lipid Association (NLA) Expert Clinical Consensus on the role of apolipoprotein (apo)B in adult patient care. This document is meant to clarify the role of apoB testing for clinicians who manage cardiovascular risk and lipid disorders, as well as health systems, payers, and medical associations. The 2021 NLA Scientific Statement, Lipid Measurements in the Management of section.